Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment
| Autor: | Wen-Bin Ding, Yan Zhou, Hao-Zheng Yang, Xiaojing Chen, Yi Ma, Long-Mei Xu, Hanbing Zou |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Organoplatinum Compounds Colorectal cancer Blotting Western Population Fluorescent Antibody Technique Antineoplastic Agents Apoptosis Mouse model of colorectal and intestinal cancer Real-Time Polymerase Chain Reaction Cancer stem cell Internal medicine Autophagy Biomarkers Tumor Tumor Cells Cultured medicine Humans RNA Messenger education Cell Proliferation education.field_of_study Reverse Transcriptase Polymerase Chain Reaction business.industry Flow Cytometry medicine.disease Oxaliplatin Drug Resistance Neoplasm Cancer cell Neoplastic Stem Cells Stem cell Colorectal Neoplasms business medicine.drug |
| Zdroj: | Cancer Letters. 361:128-136 |
| ISSN: | 0304-3835 |
| DOI: | 10.1016/j.canlet.2015.02.045 |
| Popis: | Currently, chemoresistance is an important cause of treatment failure in colorectal cancer. Cancer stem cells, which are a population of multi-potent cells with the capacity to self-renew and differentiate, have been found to participate in chemoresistance. In the present study, the chemotherapeutic drug oxaliplatin induced autophagy in colorectal cancer cell lines, which in turn protected cancer cells from apoptosis. Further results showed that oxaliplatin-induced autophagy enriched the population of colorectal CSCs and participated in maintaining the stemness of colorectal CSCs, thus making the cells more resistant to chemotherapy. Taken together, the results indicate that autophagy might enhance the chemoresistance of colorectal cancer cells by protecting the stemness and chemoresistance of colorectal CSCs. Our study demonstrates that autophagy plays a pro-survival role in colorectal CSCs subjected to oxaliplatin. Therefore, targeting autophagy may be considered as a potential therapeutic strategy to address chemoresistance in the treatment of colorectal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect